Japan Cell and Gene Therapy Market Trends, Growth, and Forecast 2025-2033

 Japan Cell and Gene Therapy Market Overview

Market Size in 2024: USD 727 Million

Market Size in 2033: USD 2,016 Million

Market Growth Rate 2025-2033: 12%

According to IMARC Group's latest research publication, the Japan cell and gene therapy market size was valued at USD 727 million in 2024. Looking forward, IMARC Group estimates the market to reach USD 2,016 million by 2033, exhibiting a CAGR of 12% from 2025-2033.

Download a sample PDF of this report: https://www.imarcgroup.com/japan-cell-gene-therapy-market/requestsample

Growth Factors in the Japan Cell and Gene Therapy Market

• Significant Advancements in Biotechnology

Advanced technologies such as gene editing, CRISPR, and CAR-T propel the creation of targeted, novel treatments. These developments established Japan as a leader in cell and gene therapy and allowed for the efficient treatment of chronic and hereditary illnesses. For instance, in December 2023, Bristol-Myers Squibb K.K. announced that it received manufacturing and marketing approval for an additional indication for Abecma® (idecabtagene vicleucel), a B-cell maturation antigen (BCMA)-directed chimeric antigen receptor (CAR) T cell immunotherapy for patients with relapsed or refractory multiple myeloma. Additionally, Synplogen Co., a synthetic biology startup part of Kobe University's Graduate School, signed a non-binding MOU with Ginkgo Bioworks to expedite global development of gene therapy platform services and DNA production in Japan.

• Rising Prevalence of Chronic and Genetic Diseases

High incidences of cancer, cardiovascular disorders, and rare genetic conditions in Japan create a strong demand for curative therapies. Cell and gene therapies address unmet medical needs, offering transformative options for patients with limited traditional treatments. The aging population and increasing incidence of hereditary and chronic illnesses further fuel demand for cutting-edge treatment alternatives that have the potential to be curative. For instance, in September 2024, Biomedical Division of PHC Corporation announced the commercial launch of LiCellMo, a live cell metabolic analyzer that visualizes metabolic changes in cell cultures, providing a more complete picture of cell activity for research uses in cell and gene therapies.

• Government and Industry Investments

Substantial government funding, academic collaborations, and industry partnerships drive research and development. These efforts expand the therapeutic pipeline, advance clinical trials, and ensure the availability of innovative treatments, boosting Japan's position in the global regenerative medicine market. Japan's proactive regulatory structure promotes innovation and speeds up commercialization through the Act on the Safety of Regenerative Medicine's accelerated approval process. For instance, in January 2024, the Development Bank of Japan Inc. announced an investment agreement with 4BIO Ventures III LP, focusing on early-stage biotech ventures utilizing innovative modalities for cell and gene therapy, RNA-based medicine, and targeted therapies.

Key Trends in the Japan Cell and Gene Therapy Market

• Expansion of CAR-T Cell Therapies

CAR-T therapy is experiencing significant growth in Japan's oncology sector, with increasing approvals and applications for various cancer types. The technology allows for precise genetic alterations and novel treatments for diseases that were previously considered incurable. Advanced CAR-T therapies are gaining traction particularly for treating relapsed or refractory multiple myeloma and other hematological malignancies. The nation's supportive regulatory framework, including accelerated approval processes, facilitates faster market entry for these innovative treatments, establishing Japan as a key player in the global CAR-T therapy market.

• Industry-Academia Collaborations

Strategic partnerships between pharmaceutical companies, research institutions, and academic centers are accelerating clinical studies and ensuring the availability of innovative therapies. For instance, in March 2024, The CiRA Foundation and Terumo Blood and Cell Technologies announced a collaboration to advance the widespread use of iPS cells for novel treatments. With Terumo BCT's enabling technologies and manufacturing expertise combined with CiRA Foundation's leading iPS cell knowledge, they aim to create an automated and clinically relevant workflow for iPS cell-derived therapies, representing a game-changer for the cell and gene therapy field.

• Growth in Contract Development and Manufacturing Organization (CDMO) Services

The expansion of CDMO services is becoming increasingly important in Japan's cell and gene therapy landscape. Companies are forming strategic partnerships to enhance manufacturing capabilities and support the growing pipeline of advanced therapies. For example, in October 2024, Teijin Limited signed a Memorandum of Understanding with Singapore-based Hilleman Laboratories to develop strategic international commercial cooperation, specifically to encourage growth of the CDMO business in cell and gene therapy industry. This trend reflects the increasing complexity of manufacturing these specialized therapies and the need for specialized expertise.

Japan Cell and Gene Therapy Industry Segmentation:

The report has segmented the market into the following categories:

Analysis by Therapy Type:

• Cell Therapy 
  • Stem Cell
  • Non-Stem Cell
• Gene Therapy

Analysis by Indication:

• Cardiovascular Disease
• Oncology Disorder
• Genetic Disorder
• Infectious Disease
• Neurological Disorder
• Others

Analysis by Delivery Mode:

• In-Vivo
• Ex-Vivo

Analysis by End User:

• Hospitals
• Cancer Care Centers
• Pharmaceutical and Biotechnology Companies
• Others

Regional Insights:

• Kanto Region
• Kansai/Kinki Region
• Central/Chubu Region
• Kyushu-Okinawa Region
• Tohoku Region
• Chugoku Region
• Hokkaido Region
• Shikoku Region

Explore full report with table of contents: https://www.imarcgroup.com/request?type=report&id=17931&flag=E

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players.

Future Outlook

The future of the Japan cell and gene therapy market is exceptionally promising, driven by continued biotechnological innovations and strong government support. The market is positioned for sustained growth as Japan maintains its leadership in regenerative medicine through substantial R&D investments and favorable regulatory frameworks. The integration of advanced technologies like CRISPR gene editing and artificial intelligence in therapeutic development will likely enhance treatment precision and effectiveness. The nation's aging population and rising prevalence of chronic diseases will continue to create robust demand for innovative therapies. Emerging technologies and expanded manufacturing capabilities through CDMO partnerships will further strengthen Japan's position as a global hub for cell and gene therapy development. With increasing clinical trial activities and expanding therapeutic pipelines, Japan is well-positioned to remain at the forefront of the regenerative medicine revolution while addressing critical unmet medical needs.

Research Methodology:

The report employs a comprehensive research methodology, combining primary and secondary data sources to validate findings. It includes market assessments, surveys, expert opinions, and data triangulation techniques to ensure accuracy and reliability.

Note: If you require specific details, data, or insights that are not currently included in the scope of this report, we are happy to accommodate your request. As part of our customization service, we will gather and provide the additional information you need, tailored to your specific requirements. Please let us know your exact needs, and we will ensure the report is updated accordingly to meet your expectations.

About Us:

IMARC Group is a global management consulting firm that helps the world's most ambitious changemakers to create a lasting impact. The company provide a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.

Contact Us:  

Street: 563-13 Kamien
Area: Iwata
Country: Tokyo, Japan
Postal Code: 4380111
Email: sales@imarcgroup.com